Filings Don’t Lie: Snow Capital Management Lp Just Opened Huge Lannett Co Inc Position

Filings Don't Lie: Snow Capital Management Lp Just Opened Huge Lannett Co Inc Position

The New Snow Capital Management Lp Holding in Lannett Co Inc

Snow Capital Management Lp filed with the SEC SC 13G form for Lannett Co Inc. The form can be accessed here: 000119312516763850. As reported in Snow Capital Management Lp’s form, the filler as of late owns 5.7% or 2,117,912 shares of the Health Care–company.

Lannett Co Inc stake is a new one for the for this institutional investor and it was filed because of activity on October6, 2016. We feel this shows Snow Capital Management Lp’s positive view for the stock. For a institutional investor managing $3.43 billion in assets and having 34+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.

Lannett Co Inc Institutional Sentiment

Latest Security and Exchange filings show 241 investors own Lannett Co Inc. The institutional ownership in Q3 2015 is very high, at 71.16% of the outstanding shares. This is increased by 2898229 the total institutional shares. 26328076 were the shares owned by these institutional investors. In total 51 funds opened new Lannett Co Inc stakes, 93 increased stakes. There were 45 that closed positions and 73 reduced them.

Morgan Dempsey Capital Management Llc is an institutional investor bullish on Lannett Co Inc, owning 61540 shares as of Q3 2015 for 0.90% of its portfolio. Jw Asset Management Llc owns 31844 shares or 0.48% of its portfolio. K3 Parametrica Management Ltd have 1.85% of their stock portfolio for 7075 shares. Further, Gotham Asset Management Llc reported stake worth 0.57% of its US stock portfolio. The FL Zpr Investment Management owns 199675 shares. Lannett Co Inc is 10.12% of the manager’s US portfolio.

Business Profile

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Snow Capital Management Lp website.

Insitutional Activity: The institutional sentiment increased to 0.88 in Q2 2016. Its up 0.07, from 0.81 in 2016Q1. The ratio increased, as 38 funds sold all Lannett Company, Inc. shares owned while 51 reduced positions. 27 funds bought stakes while 51 increased positions. They now own 27.61 million shares or 4.85% less from 29.01 million shares in 2016Q1.

Bnp Paribas Arbitrage has invested 0% of its portfolio in Lannett Company, Inc. (NYSE:LCI). Teachers Advsr accumulated 44,360 shares or 0% of the stock. Lpl Financial Limited Liability accumulated 0.01% or 29,661 shares. Cubist Systematic Strategies Limited Liability Corp accumulated 0% or 1,880 shares. Northern Corporation has 362,656 shares for 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 0% of its portfolio in the stock. Mesirow Fincl Inv Mgmt holds 0.02% of its portfolio in Lannett Company, Inc. (NYSE:LCI) for 11,315 shares. Alliancebernstein L P last reported 43,450 shares in the company. Dupont Capital Mngmt has 82,305 shares for 0.04% of their US portfolio. Commerzbank Aktiengesellschaft Fi has 18,455 shares for 0% of their US portfolio. The Minnesota-based Ameriprise Fincl has invested 0.01% in Lannett Company, Inc. (NYSE:LCI). Charlemagne accumulated 0.12% or 6,323 shares. Zpr Investment Management accumulated 166,695 shares or 7.51% of the stock. Moreover, California Pub Employees Retirement Systems has 0% invested in Lannett Company, Inc. (NYSE:LCI) for 89,100 shares. Barclays Public Ltd, a United Kingdom-based fund reported 46,105 shares.

Insider Transactions: Since August 31, 2016, the stock had 0 insider buys, and 3 selling transactions for $416,823 net activity. 4,334 shares were sold by Landis G. Michael, worth $139,988 on Thursday, September 15. Maher James M. had sold 1,478 shares worth $50,119 on Thursday, September 1.

About 9,854 shares traded hands. Lannett Company, Inc. (NYSE:LCI) has declined 5.08% since April 7, 2016 and is downtrending. It has underperformed by 9.87% the S&P500.

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The company has a market cap of $722.52 million. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. It currently has negative earnings. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.

Lannett Company, Inc. (NYSE:LCI) Ratings Coverage

Out of 8 analysts covering Lannett (NYSE:LCI), 6 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 75% are positive. $70 is the highest target while $3 is the lowest. The $42.07 average target is 111.41% above today’s ($19.9) stock price. Lannett has been the topic of 20 analyst reports since July 21, 2015 according to StockzIntelligence Inc. Roth Capital maintained it with “Buy” rating and $27.50 target price in Thursday, March 24 report. Roth Capital maintained the shares of LCI in a report on Thursday, September 3 with “Buy” rating. The firm earned “Strong-Buy” rating on Monday, September 7 by Zacks. The stock has “Hold” rating given by Craig Hallum on Thursday, November 5. The company was upgraded on Thursday, February 4 by Craig Hallum. The rating was maintained by Roth Capital with “Buy” on Friday, March 11. The stock has “Hold” rating given by Deutsche Bank on Wednesday, June 29. Susquehanna initiated Lannett Company, Inc. (NYSE:LCI) on Tuesday, July 21 with “Positive” rating. The stock of Lannett Company, Inc. (NYSE:LCI) has “Buy” rating given on Wednesday, August 26 by Roth Capital. On Thursday, September 3 the stock rating was maintained by TH Capital with “Buy”.

More important recent Lannett Company, Inc. (NYSE:LCI) news were published by: Businesswire.com which released: “LANNETT INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn …” on November 08, 2016, also Fool.com published article titled: “Why Lannett Company, Inc. Shares Got Pummeled Today”, Businesswire.com published: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Lannett …” on November 03, 2016. More interesting news about Lannett Company, Inc. (NYSE:LCI) was released by: Prnewswire.com and their article: “SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of …” with publication date: November 04, 2016.

According to Zacks Investment Research, “Lannett, Inc. manufactures and distributes pharmaceutical products sold under generic names and historically has manufactured and distributed pharmaceutical products sold under its trade or brand names. In addition, the Company contract manufactures and private labels pharmaceutical products for other companies.”

LCI Company Profile

Lannett Company, Inc., incorporated on December 3, 1991, develops, makes, markets and distributes generic versions of brand pharmaceutical products. The Firm makes and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Firm has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment